One of the aspects of pregnancy after 35 that many women find simultaneously important and overwhelming is prenatal genetic testing. A range of screening and diagnostic tests are available, each designed to provide different types of information about the developing pregnancy. Understanding what each test can and cannot tell you — and recognizing that choosing which tests to pursue is a personal decision shaped by individual values and circumstances — can help make the landscape feel more navigable.
The goal of this overview is to provide a factual summary of the main testing options currently available, grounded in clinical guidelines. It is not a substitute for a conversation with your OB/GYN or maternal-fetal medicine specialist, who can provide recommendations tailored to your specific health history and pregnancy.
Why Testing Conversations Happen More Often After 35
The primary reason prenatal genetic testing is discussed with particular frequency for women over 35 is the age-related increase in the risk of chromosomal conditions, most notably Down syndrome (trisomy 21). According to the American College of Obstetricians and Gynecologists (ACOG), the risk of a chromosomally affected pregnancy increases with maternal age, as chromosomal errors during egg formation become somewhat more common over time.
However, ACOG’s current guidance recommends that all pregnant women — regardless of age — be offered information about both screening and diagnostic options. The prior practice of automatically recommending invasive diagnostic testing for women 35+ has largely been replaced with a more individualized approach in which women are informed of their options and make their own decisions about which tests, if any, align with their values and circumstances.
Screening Tests: What They Can Tell You
Screening tests evaluate whether a pregnancy may be at higher-than-average risk for certain conditions, but they do not provide a definitive diagnosis. A positive or high-risk screening result indicates a need for further evaluation; it does not confirm that a condition is present. Most pregnancies that screen positive are ultimately found to be unaffected after further testing.
Cell-Free DNA Screening (cfDNA / NIPT)
Cell-free DNA screening, often called NIPT (non-invasive prenatal testing), analyzes small fragments of fetal DNA that circulate in the mother’s blood. This test can screen for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and sex chromosome conditions with relatively high sensitivity and specificity compared to earlier screening methods. Some versions also screen for microdeletion syndromes, though the evidence supporting these additions is more limited.
NIPT is typically offered from 10 weeks of pregnancy onward. It’s important to understand that even with high sensitivity, cfDNA screening is not a diagnostic test — false positives and false negatives can occur, and positive results typically prompt confirmation through diagnostic testing.
First Trimester Combined Screening
This approach combines an ultrasound measurement of nuchal translucency (the fluid space at the back of the fetal neck) with blood markers (PAPP-A and hCG) to generate a risk assessment for chromosomal conditions. Offered between 11 and 14 weeks, it provides an individualized risk calculation. While less sensitive than cfDNA screening for the most common chromosomal conditions in older women, it has the advantage of also evaluating certain structural features of the pregnancy.
Diagnostic Tests: Definitive Answers With Procedural Risk
Diagnostic tests can provide definitive chromosomal information — they can confirm or rule out a chromosomal condition with high certainty. However, both currently available diagnostic tests involve procedural intervention and carry a small risk of pregnancy loss.
Chorionic Villus Sampling (CVS)
CVS involves taking a small sample of placental tissue, typically between 10 and 13 weeks of pregnancy. The sample contains fetal cells, which are analyzed for chromosomal and genetic information. CVS provides early definitive results, which some women value for decision-making. The procedure-related risk of pregnancy loss is generally cited in the range of 0.5-1% in experienced centers, though rates vary by provider and technique.
Amniocentesis
Amniocentesis involves withdrawing a small amount of amniotic fluid, typically between 15 and 20 weeks. The fluid contains fetal cells that can be analyzed chromosomally. Like CVS, it provides definitive information. The procedure-related loss rate is similarly low in experienced centers — generally quoted around 0.1-0.3% — and the later timing means more complete anatomical information is available from concurrent ultrasound evaluation.
Making Decisions About Testing
Choosing among these testing options — or choosing not to test — is a genuinely personal decision that depends on individual values, what information would be useful to you, how you would use that information, and your comfort with procedural risk versus uncertainty. There is no universally “right” answer.
Some women want as much information as possible as early as possible, regardless of what they might do with it. Others prefer to allow the pregnancy to progress without genetic testing. Others seek testing primarily to plan and prepare. Genetic counselors — healthcare professionals specialized in helping people understand genetic testing and results — can be particularly helpful conversation partners when navigating these decisions, and many maternal-fetal medicine practices offer genetic counseling as part of their care.
For women navigating pregnancy after 35 and considering their full care pathway, understanding the testing landscape is one part of building an informed picture of the pregnancy journey ahead.
Frequently Asked Questions
Is prenatal genetic testing required at 35?
No — prenatal genetic testing is offered, not required. ACOG recommends that all pregnant women be informed about available options and supported in making their own decisions. Choosing not to pursue any genetic testing is a legitimate and common choice.
How accurate is NIPT/cfDNA screening?
For trisomy 21 in particular, cfDNA screening has detection rates reported in the range of 99% in high-risk populations, with low false positive rates. However, performance varies somewhat by condition, gestational age, and individual factors like body weight. All screening results — positive or negative — should be interpreted in consultation with a healthcare provider.
What happens if a screening test shows high risk?
A high-risk screening result typically prompts a discussion with your OB/GYN or a referral to a maternal-fetal medicine specialist or genetic counselor. Diagnostic testing (CVS or amniocentesis) may be offered to confirm or rule out the condition identified. A high-risk result does not mean a diagnosis has been made, and many women with high-risk screening results go on to have unaffected pregnancies after diagnostic confirmation.
Can prenatal testing detect all genetic conditions?
No — current prenatal screening and even comprehensive diagnostic testing cannot detect all possible genetic or chromosomal conditions. Prenatal testing evaluates specific conditions based on the test design. A normal result significantly reduces but does not eliminate the possibility of genetic difference. Your healthcare provider can describe what a specific test does and does not evaluate.
Key Takeaways
- ACOG recommends that all pregnant women — regardless of age — be offered information about prenatal screening and diagnostic options.
- Screening tests (like cfDNA/NIPT and first trimester combined screening) provide risk assessments, not diagnoses; diagnostic tests (CVS and amniocentesis) provide definitive chromosomal information but carry small procedural risks.
- Decisions about which tests to pursue are personal and should be based on individual values, information needs, and comfort with procedural risk.
- Genetic counselors are valuable resources for understanding testing options and interpreting results in a nuanced, non-anxiety-amplifying context.
- Working with an OB/GYN or maternal-fetal medicine specialist who can tailor recommendations to your specific pregnancy provides the most useful foundation for testing decisions.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.